Abstract
This paper is devoted to open-label Phase III, where 670 patients with imatinib-reistant or intolerant CML-CP were randomly divided between four dasatinib 100 mg once daily, twice daily 50 mg. 140 mg once daily or 70 mg twice daily. In study was monitored and evaluated effectiveness of treatment, hematological and non-haematologic adverse reactions in a different regimen.
It was found that dasatinib 100 mg once daily retains force as a dose 70 mg twice daily with less toxicity. Intermittent target inhibition of tyrosine kinase inhibitors may maintain the effectiveness with a reduction in adverse effects.